CORONA REMEDIES LIMITED vs SUN PHARMACEUTICAL IND L
A side-by-side comparison of CORONA REMEDIES LIMITED (CORONA) and SUN PHARMACEUTICAL IND L (SUNPHARMA) — valuation, profitability, growth, and financial health — to help you judge which is the stronger buy today.
On the numbers, SUN PHARMACEUTICAL IND L leads CORONA vs SUNPHARMA on 8 of 14 metrics. See the breakdown below — the right pick still depends on your goals (value vs growth, risk appetite).
- Valuation13
- Profitability22
- Growth20
- Size & financial health13
Each axis shows this group's split of that metric, scaled so the leader sits at the edge. Relative to each other, not an absolute score.
Valuation
SUNPHARMA takes 3/4How expensive each stock is relative to its earnings and book value. Lower usually means cheaper.
Profitability
EvenHow efficiently each company turns capital and sales into profit. Higher is better.
Growth
CORONA takes 2/2Three-year compounded growth. Faster-growing businesses can justify a higher valuation.
Size & financial health
SUNPHARMA takes 3/4Scale and balance-sheet strength. Bigger revenue/profit and lower debt are generally safer.
- + ["Company has delivered good profit growth of 23.3% CAGR over last 5 years", "Company has a good return on equity (ROE) track record: 3 Years ROE 26.5%", "Company has been maintaining a healthy dividend payout of 29.4%"]
- − ["Stock is trading at 17.0 times its book value", "Company might be capitalizing the interest cost"]
- + ["Company is almost debt free.", "Company has been maintaining a healthy dividend payout of 34.1%"]
- − ["The company has delivered a poor sales growth of 11.8% over past five years."]
This comparison is for informational purposes only and is not investment advice. Please consult a SEBI-registered advisor before investing.